Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human CD22 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Sinomab Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The **recombinant human CD22 monoclonal antibody** is a biologic therapy developed by **Shenzhen Longrui Pharmaceutical** (a subsidiary of **SinoMab BioScience**) for the treatment of autoimmune diseases, specifically **systemic lupus erythematosus (SLE)**. It targets the **CD22** antigen (also known as Siglec-2), a transmembrane glycoprotein expressed on the surface of mature B lymphocytes. CD22 acts as an inhibitory co-receptor for B-cell receptor (BCR) signaling, and its modulation helps regulate B-cell activation, migration, and survival. By binding to CD22, this antibody aims to dampen the B-cell hyperactivity that characterizes SLE. It is closely related to the chimeric anti-CD22 antibody **suciraslimab (SM03)** but is designed as a fully recombinant human version to potentially improve safety and reduce immunogenicity. The drug has been evaluated in Phase 1 clinical trials (e.g., CTR20130117) to assess its pharmacokinetics, safety, and preliminary efficacy.
- Other names
- recombinant human anti-CD22 monoclonal antibody
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on recombinant human CD22 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human CD22 monoclonal antibody.